Onsdag 21 Januari | 16:53:15 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2027-02-24 08:30 Bokslutskommuniké 2026
2026-11-02 08:30 Kvartalsrapport 2026-Q3
2026-08-05 08:30 Kvartalsrapport 2026-Q2
2026-05-26 N/A Årsstämma
2026-05-18 08:30 Kvartalsrapport 2026-Q1
2026-02-27 08:30 Bokslutskommuniké 2025
2025-11-14 - Kvartalsrapport 2025-Q3
2025-08-01 - Kvartalsrapport 2025-Q2
2025-05-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2025-05-26 - Årsstämma
2025-05-22 - Kvartalsrapport 2025-Q1
2025-03-27 - Bokslutskommuniké 2024
2024-12-30 - Extra Bolagsstämma 2025
2024-10-24 - Kvartalsrapport 2024-Q3
2024-10-04 - Extra Bolagsstämma 2024
2024-07-18 - Kvartalsrapport 2024-Q2
2024-04-26 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2024-04-25 - Årsstämma
2024-04-18 - Kvartalsrapport 2024-Q1
2024-02-16 - Bokslutskommuniké 2023
2023-10-25 - Kvartalsrapport 2023-Q3
2023-07-18 - Kvartalsrapport 2023-Q2
2023-04-27 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2023-04-26 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-09 - Kvartalsrapport 2022-Q3
2022-08-17 - Kvartalsrapport 2022-Q2
2022-05-19 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2022-05-17 - Årsstämma
2022-05-05 - Kvartalsrapport 2022-Q1
2022-02-25 - Bokslutskommuniké 2021
2021-12-14 - Extra Bolagsstämma 2021
2021-11-16 - Kvartalsrapport 2021-Q3
2021-08-17 - Kvartalsrapport 2021-Q2
2021-05-14 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning MAGLE 0.00 SEK
2021-04-18 - Årsstämma
2021-02-25 - Bokslutskommuniké 2020
2020-11-27 - Extra Bolagsstämma 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-14 - Kvartalsrapport 2020-Q2

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriMedicinteknik
Magle Group bygger på strategiska förvärv som syftar till att driva tillväxt och diversifiera risker. Idag omfattar koncernen tre verksamhetsområden. Magle Chemoswed, en kontraktsutvecklings- och tillverkningsorganisation (CDMO). Magle PharmaCept, ett försäljnings- och marknadsföringsföretag för utveckling och direktförsäljning av koncernens medicintekniska produkter, och Magle Biopolymers A/S, en specialiserad tillverkningsorganisation för Dextran-teknologi.

Intresserad av bolagets nyckeltal?

Analysera bolaget i Börsdata!

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

2026-01-21 13:52:00

Magle Group today announces that Fredrik Andersson, Chief Operating Officer, will step down from his position during the coming months, as part of a planned leadership transition. This decision has been made for personal reasons, as Fredrik looks to open a new chapter in life with more time for family and the opportunity to explore other professional avenues.

Fredrik has served Magle Group for more than 25 years, contributing significantly to the development and operational success of the business. His leadership and experience have been central in supporting the Group’s evolution from a development-focused company into a fully integrated life sciences organisation.

Aaron Wong, Interim Chief Executive Officer, commented:
“Fredrik has been a cornerstone of Magle Group’s operations and culture. Over the years, he has helped embed the structures and processes that continue to underpin our success. While he has chosen to step back in due course, the transition is being carefully managed, and we are ensuring continuity by drawing on the strength of our existing leadership team and the operational frameworks Fredrik helped establish. On behalf of Magle Group, I would like to thank him for his dedication and wish him the very best for the future.”

Fredrik Andersson commented:
“It has been a privilege to contribute to Magle Group’s journey over the years. As the company now enters its next phase, I feel the time is right for me to focus more on my family and to explore new opportunities outside the organisation. I remain fully committed to supporting a smooth transition and am confident that the business is in a strong position to continue delivering on its strategy.”

The Company has a clear continuity plan in place, and the operational leadership transition will be carried out over the coming period in a structured and collaborative manner. Magle Group remains firmly focused on executing its growth strategy and operational priorities without disruption.